Article Data

  • Views 358
  • Dowloads 137

Original Research

Open Access

Study on the mechanism of Zhimu in the treatment of ovarian cancer based on network pharmacology

  • Sufan Guo1
  • Chunting Peng1
  • Qisheng Su1
  • Zheng Yang1
  • Xiaohong Li1
  • Wuning Mo1,*,

1Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China

DOI: 10.22514/ejgo.2023.059 Vol.44,Issue 4,August 2023 pp.76-82

Submitted: 18 August 2022 Accepted: 07 November 2022

Published: 15 August 2023

*Corresponding Author(s): Wuning Mo E-mail:


We aimed to investigate the mechanism of action of Zhimu in the treatment of ovarian cancer (OC) using network pharmacology. OC targets were screened using the DisGeNET and Online Mendelian Inheritance in Man databases. Common OC and Zhimu targets were identified using the Traditional Chinese Medicine System Pharmacology, UniProt databases, and Venny 2.1.0. The protein-protein interaction (PPI) network in the Search Tool for the Retrieval of Interacting Genes/Proteins database was created using Zhimu/OC targets and a Zhimu active ingredient-target-pathway network in the Cytoscape 3.9.1 software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted using the Metascape database. And overall, 15 active ingredients in addition to 93 related targets were identified. The PPI network had 52 targets that overlapped with it, with the 10 most relevant targets being the tumour protein p53, tumour necrosis factor, serine/threonine kinase 1, vascular endothelial growth factor A, caspase-3, prostaglandin G/H synthase-2, hypoxia-inducible factor-1 alpha, interleukin-1 beta, heat-shock protein 90-alpha, and progesterone receptor. According to GO and KEGG analyses, Zhimu and OC had the nuclear factor NF-kappaB signalling pathway, oxidative stress, and the advanced glycation end product (AGE)/the receptor for the advanced glycation end product (RAGE) signalling pathway as common targets. This study highlighted the active ingredients in Zhimu and identified potential molecular therapeutic mechanisms for the treatment of OC. It also provided suggestions and directions for future research into molecular mechanisms.


Cancer; Network pharmacology; Molecular mechanism; Zhimu

Cite and Share

Sufan Guo,Chunting Peng,Qisheng Su,Zheng Yang,Xiaohong Li,Wuning Mo. Study on the mechanism of Zhimu in the treatment of ovarian cancer based on network pharmacology. European Journal of Gynaecological Oncology. 2023. 44(4);76-82.


[1] Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Medicine. 2019; 8: 1958–1975.

[2] Cui Y, Shu X-O, Gao Y, Wen W, Ruan Z-X, Jin F, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Research and Treatment. 2004; 85: 263–270.

[3] Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO. The use of complementary and alternative medicine among Chinese women with breast cancer. Journal of Alternative and Complementary Medicine. 2008; 14: 1049–1055.

[4] Yu Y, Yan L, Wang X, Li L, Zheng W, Gao H. Study on the effects of Chinese materia medica processing on the hypoglycemic activity and chemical composition of anemarrhenae rhizoma. Evidence-Based Complementary and Alternative Medicine. 2021; 2021: 6211609.

[5] Han J, Yang N, Zhang F, Zhang C, Liang F, Xie W, et al. Rhizoma anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents. Journal of Ethnopharmacology. 2015; 172: 368–376.

[6] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics. 2014; 6: 13.

[7] Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications. 2019; 10: 1523.

[8] Penny SM. Ovarian cancer: an overview. Radiologic Technology. 2020; 91: 561–575.

[9] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice & Research. Clinical Obstetrics & Gynaecology. 2017; 41: 3–14.

[10] Yang S, Si L, Jia Y, Jian W, Yu Q, Wang M, et al. Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways. Journal of BUON: Official Journal of the Balkan Union of Oncology. 2019; 24: 975–981.

[11] Wang P, Zhang J, Xiong X, Yuan W, Qin S, Cao W, et al. Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells. Oncology Reports. 2019; 41: 2321–2328.

[12] Guo X, Ding X. Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signalling pathways. Oncology Letters. 2018; 15: 9537–9542.

[13] Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Investigation. 2008; 26: 822–829.

[14] Chu S-H, Liu Y-W, Zhang L, Liu B, Li L, Shi J-Z, et al. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Molecular Biology Reports. 2013; 40: 1–6.

[15] Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signalling pathway in ovarian cancer: biological and therapeutic significance. Seminars in Cancer Biology. 2019; 59: 147–160.

[16] Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signalling to promote cancer. Molecular and Cellular Biochemistry. 2021; 476: 585–598.

[17] Yang W, Liu L, Li C, Luo N, Chen R, Li L, et al. TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway. Cell Death & Disease. 2018; 9: 908.

[18] Li Y, Wang S, Li P, Li Y, Liu Y, Fang H, et al. Rad50 promotes ovarian cancer progression through NF‐κB activation. Journal of Cellular and Molecular Medicine. 2021; 25: 10961–10972.

[19] Wang X, Wang F, Zhang ZG, Yang XM, Zhang R. STK3 suppresses ovarian cancer progression by activating NF-κB signaling to recruit CD8+ T-cells. Journal of Immunology Research. 2020; 2020: 7263602.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time